Transferrin and iron requirements of embryonic mesoderm cells cultured in hydrated collagen matrices.
Very early embryonic mesoderm cells were taken from the primitive streak-stage chick embryo and cultured in a matrix of type I collagen in the presence of serum. Previous work has shown that under these conditions cells do not leave the explant and move in the collagen in the absence of supplemented avian transferrin. Cells explanted onto tissue culture plastic in the presence of serum do not require this transferrin supplement. These observations were investigated further by culturing cells in collagen in the presence of the lipophilic iron chelator, ferric pyridoxal isonicotinoyl hydrazone (FePIH), which can replace transferrin as an iron-delivery agent. Under conditions in which FePIH could effectively stimulate chick embryo myoblast growth, no such long-term stimulation was obtained with the early mesoderm cells in collagen. This suggested that for mesoderm cells, FePIH could not replace transferrin. Antibody to the transferrin receptor and to transferrin itself inhibited growth of myoblasts in collagen and on plastic, and of mesoderm cells in collagen. Mesoderm cells on plastic, however, were refractory to the presence of the antibody directed to the receptor and seemed to show a low dependency on transferrin-delivered iron under these conditions, inasmuch as antiserum to transferrin itself only caused a partial inhibition of outgrowth. The results suggest that mesoderm cells in collagen require transferrin for both iron uptake and for another unspecified function. It is consistent with the results to propose that transferrin binding might modulate the cells' attachment to collagen, thus influencing outgrowth. The distribution of the actin cytoskeleton in mesoderm cells actively migrating in collagen, such as in the presence of transferrin, suggests a stronger attachment to the collagen than nonmigrating cells.
Sanders
E J
EJ
Department of Physiology, University of Alberta, Edmonton, Canada.
Cheung
E
E
D000199:Actins / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000502:physiology; D002449:Cell Aggregation; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D003094:Collagen; D005347:Fibroblasts / Q000166:cytology; D007501:Iron / Q000502:physiology*; D007502:Iron Chelating Agents; D007538:Isoniazid / Q000031:analogs & derivatives / Q000494:pharmacology; D008648:Mesoderm / Q000166:cytology*; D008854:Microscopy, Electron; D009132:Muscles / Q000166:cytology; D011730:Pyridoxal / Q000031:analogs & derivatives / Q000494:pharmacology; D014168:Transferrin / Q000276:immunology / Q000494:pharmacology / Q000502:physiology*
D000199:Actins; D000906:Antibodies; D007502:Iron Chelating Agents; D014168:Transferrin; D011730:Pyridoxal; C021079:pyridoxal isonicotinoyl hydrazone; D003094:Collagen; D007501:Iron; D007538:Isoniazid